Tweets
Saturday: ACR 2022 Daily Recap https://t.co/3WGcxsEtOj
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Emerging and exciting treatments in RA: #ACR22 preview
https://t.co/5JtblF9MxE https://t.co/oYSiLguLkJ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Are DNA methylation marks the new seronegative RA biomarkers?
Riskedal et al. propose a new model based on whole-blood DNAm profiles
Sens 90%, Spe 88%, Accuracy 89% for classification of RA
Accuracy RA Sero+ 100%, RA Sero- 75%
https://t.co/3occAQPZ1u Abs#0531 #ACR22 @Rheumnow https://t.co/QXhMxyWC8g
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Terrier @TerrierBen . Pooled analysis of MAINRITSAN trials. For major relapse at 84 months RTX>AZA HR 2.5. RTX fixed-dose>tailored HR 3. RTX 18 vs 36 months equal HR 1.2 (although 78% vs 70% relapse free). @RheumNow #ACR22 Abstr#0527 https://t.co/IWQmcGeRiW
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
So great to be in person for higher learning in #rheumatology #ACR22 @RheumNow also the onliners are welcomed https://t.co/JIcyV7v1Ws
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Khanna @sclerodermaUM. SLS-III MMF+Pirfenidone vs MMF alone in SSc-ILD. Underpowered due to COVID (51 vs 150). No difference FVC 18 months ?more rapid improvement in combo. Better HRCT, PROs in combination. Need another study! @RheumNow #ACR22 Abstr#0520 https://t.co/K2Ne6PSHkS https://t.co/P6A7OJpzCf
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#Abstr 0542 ASAS EULAR Recommendations for Management of axSpA
'Absence of response to treatment should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities.'
@RheumNow #ACR22
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
18mo data of ARIAA study (6mo ABA in pre-RA):
12mo after discontinuation
Progression to RA ABA 35% vs PBO 57% p=0.008
Improvement in synovitis, osteitis & tenosynovitis ABA 57% vs. 29% PBO
Enough to move into clinical application?
https://t.co/2CDN9M31mB
Abs#0530 #ACR22 @Rheumnow https://t.co/R54AokGSiK
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Jayne et al. ADVOCATE avacopan trial sub-analysis looking at patients eGFR<=20. Significantly better reduction albuminuria and increase eGFR. Numerically better recovery, lower GC, less infection @RheumNow #ACR22 Abstr#0525 https://t.co/v4ffiqfsyt https://t.co/9pK0Pn6IOj
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
🔎Look! Urinary biomarkers vs. UPCR in tx response of #lupus nephritis by Dr @andreafava et al
🦋A decline in several urinary BMs at 3 mos outperformed UPCR in predicting the 1 yr response.
Urinary BMs as surrogate endpts in trials?🤔#ACR22 @RheumNow ABST0536 https://t.co/kMWmsK8mnO
sheila @RHEUMarampa ( View Tweet )
3 years 8 months ago
@GuyKatzMD @zach_wallace_md et al. Hypocomplementemia seen in 30% IgG4-RD. More organs involved (mean 4.3 vs 2.9). More likely to have serum IgG4 above ULN (89%vs74%) and 5XULN (52%vs28%) @rheumnow #ACR22 Abstr#0144 https://t.co/bVRTuh3dsU https://t.co/3SHEbg2tbR
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Sanchez-Bilbao et al. IV vs SC tocilizumab in 471 GCA patients. No differences in sustained remission or glucocorticoid-sparing. Numerically more AEs in IV but this due to longer follow up, no difference when corrected @rheumnow #ACR22 Abstr#0146 https://t.co/EB2RMYdzAr https://t.co/4xIMH1PIt3
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
